Form 4: Veracyte Director Sells Shares Under 10b5-1 Plan

Veracyte Director Evan Jones sold 1,106 shares of common stock for approximately $50.25 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Evan Jones, a Director of Veracyte, Inc. (VCYT), sold 1,106 shares of common stock.
• The transaction occurred on November 25, 2025.
• The shares were sold at a weighted average price of $50.2493 per share, with individual sale prices ranging from $50.005 to $50.66.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Jones on December 9, 2024.
• Following this transaction, Mr. Jones directly beneficially owns 29,362 shares of Veracyte common stock.

Sentiment

Score: 4

Explanation: While the sale was pre-planned under a 10b5-1 plan, insider selling, even routine, can sometimes be interpreted with slight caution by the market, indicating a minor negative sentiment. However, the pre-planned nature mitigates significant negative impact.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived with slight caution by the market as it reduces the insider's direct stake in the company.

Future Outlook

NA

Industry Context

This is a routine insider transaction report (Form 4) for Veracyte, Inc., a company operating in the diagnostics and life sciences industry. It does not provide specific industry-wide context or trends.

Stakeholder Impact

• Shareholders: May observe a slight reduction in a director's direct ownership, though the pre-planned nature under Rule 10b5-1 suggests it is not based on new material non-public information.

Key Dates

Keywords

Veracyte, VCYT, Insider Trading, Form 4, Evan Jones, Stock Sale, 10b5-1 Plan, Director Transaction